Acer Therapeutics Inc (Nasdaq:ACER) Trades At Over Twice The 52 Week Low

Acer Therapeutics Inc (Nasdaq:ACER)

August 1st, 2018

Acer Therapeutics Inc closed Monday up 18.28%, a $3.29 increase to close on $21.29. The stock continues to trade well at 190% of its 52 week low of $7.35. In addition to finishing higher, trading volumes were solid at 2,885% of normal which can indicate investors see opportunities. Be aware that the Piotroski Score1 is calculated to be 2, which is very low as the scale goes from 0-9. This is considered to be a weak score in terms of financial strength.

ACER outperformed the rest of the Healthcare sector which went up 0.05% today.

Acer Therapeutics Inc Info

As of September 19, 2017, Opexa Therapeutics, Inc. was acquired by Acer Therapeutics Inc., in a reverse merger transaction. Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The company’s lead product candidate is Tcelna, a T-cell immunotherapy for the treatment of patients with secondary progressive MS. It is also developing OPX-212, an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is headquartered in The Woodlands, Texas.

All amounts in USD unless otherwise indicated

(1) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Acer Therapeutics Inc’s score is ), and 9 is the best.

ACER daily update
ACER daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.